마우스 피부와 구강의 유전자 기능을 동시에 평가하기 위한 Vivo CRISPR/Cas9 스크리닝

Executive Industry Relevance

In vivo CRISPR/Cas9 screening enables rapid, multiplexed functional interrogation of gene roles in disease-relevant mouse tissues, accelerating target validation and mechanistic de-risking in oncology discovery. This approach reduces the time and cost barriers of traditional GEMMs, supporting earlier, data-driven portfolio triage and prioritization. Its adaptability across tissues and gene perturbation types positions it as a scalable platform for preclinical model innovation.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Enables simultaneous functional assessment of hundreds of candidate tumor suppressor genes in vivo.
• Supports mechanistic de-risking by clarifying gene roles in tissue-specific oncogenesis.
• Facilitates rapid hypothesis testing and target prioritization for downstream validation.

Screening & Assay Development

• Generates validated, multiplexed knockout models for robust screening of gene function.
• Provides quantitative readouts via next-generation sequencing of sgRNA representation.
• Improves reproducibility and scalability compared to single-gene knockout workflows.

Translational & Preclinical Research

• Aligns preclinical models with human disease biology by enabling tissue- and context-specific gene perturbation.
• Supports continuity from discovery through preclinical validation by enabling single-cell profiling of transduced cells.
• Reduces late-stage attrition risk by providing early, in vivo functional evidence for candidate targets.

Pipeline & Workflow Integration

This in vivo CRISPR screening method bridges early discovery and preclinical model development, enabling direct functional genomics in relevant tissues before lead identification.

• Discovery Biology: Accelerates hypothesis-driven gene function testing and pathway mapping in disease-relevant systems.
• Screening: Delivers multiplexed, quantitative outputs for robust comparison of gene perturbations.
• Analytics: Leverages next-generation sequencing for precise measurement of sgRNA enrichment and depletion.
• Translational Research: Supports biomarker discovery and mechanistic alignment with clinical phenotypes.
• Enterprise Reuse: Adaptable protocol for diverse tissues, gene sets, and disease models across R&D programs.

Operational & Enterprise Impact

• Scientific Value: Increases predictive confidence in target selection and reduces mechanistic ambiguity.
• Operational Value: Streamlines model generation, enhances reproducibility, and enables high-throughput functional genomics.
• Strategic Value: Improves go/no-go decision quality and capital allocation by providing early, multiplexed in vivo data.
• Portfolio Impact: Enables risk-adjusted prioritization and advancement of validated targets.

Implementation Considerations

• Requires expertise in in utero surgery, CRISPR library design, and next-generation sequencing analytics.
• Demands access to ultrasound-guided injection systems and high-titer lentiviral production capabilities.
• Standardization of sgRNA library representation and viral delivery is critical for reproducibility.
• Protocol can be adapted to other organs or CRISPR modalities with appropriate optimization.
• Careful control of viral titer and injection parameters is necessary to avoid confounding effects from multiple sgRNA integration.

Biopharma FAQs